Leading the Horizon External Manufacturing team with responsibility for Horizon's large and small molecule portfolio consisting of four large molecules and six small molecules across over 20 CMOs, with combined global sales of approx. $4 billion• Led the successful expansion of TEPEZZA (monoclonal antibody) manufacturing at both the drug substance and drug product CMOs to meet the rapid growth in demand – launch to $2 billion in two years• Successfully achieved 100% delivery of all finished products for past three years ensuring 100% of patients received their medicines on time• Led the tech transfer preparation for Horizon's new Waterford facility until the new Waterford management team was onboarded• Reorganized cross-functional product delivery teams to improve collaboration and results

Led the Global Engineering function with responsibility for managing global capital expenditure (€250 million budget) and factory of the future roadmap and implementation. • Led strategic portfolio review of Ipsen capital investments as part of cost cutting measures, identifying synergies and savings across the group enabling >40% reduction in investments• Led the design for a new sterile liquid fill and lyophilised drug product manufacturing facility at Ipsen Wrexham• Developed “Factory of the Future” roadmap for the global tech operations group• Identified and implemented suitable “FOF use cases” as well as key technologies including MES and advanced automation solutions across the Ipsen's manufacturing sites• Streamlined capex approval process and introduced new monthly KPIs and reporting for capital projects.• Implemented a global maintenance efficiency program with savings identification of >20% of maintenance expenditure.

•Managed the rapid capacity increase required to handle 30% year on year growth for Ipsen’s top product Somatuline with sales increasing from €250 million to €1.2 billion•Led €150 million investment program totally transforming the site in all aspects and a further €30 million investment under way with all major projects completed on time and budget.•Led the implementation of Behavioural Based Safety program on site which resulted in 7 years without a lost time accident. Achieved ISO 14001 and OSHA 18001 certification in 2018.•Led strong communication strategy within organisation to build high trust and engagement across all levels in the company and enable the business to achieve its goals and objectives. Achieved highest engagement score of all Ipsen sites and offices in biannual global survey. •Achieved Great Place to Work Status for Dublin in 2018 and in 2019 achieving thirteenth and eighth place respectively for medium size companies in Ireland. •Proven track record of leading successful FDA and HPRA inspections, well networked and expertise in regulatory affairs as well as extensive experience in dealing with the EPA.•De-risked operations at Dublin and achieved highest possible Factory Mutual risk score (87 out of 87), which is critical for the Dublin site as it is the sole source supplier of APIs for Ipsen's top two products. •Led the Dublin site to achieve Shingo silver level as assessed by Manufacturing Institute. Implemented extensive Tier system for managing day to day operations. Strong focus on problem solving and delivering on aggressive productivity and efficiency savings. Improved the yields of Ipsen #1 product by over 40%.

•Reorganised the Operations function - set up process engineering dept., implemented PMBOK system for managing capital projects, reorganised production department, expanded the responsibility of purchasing dept.•Led the implementation of Lean and Six Sigma on site introducing a culture of continuous improvement. •Repositioned safety on site, implementing new health and safety management system and made safety a top priority for everyone.

Responsible for operation of all end of line treatment systems including incinerator (the largest incinerator in Ireland), solvent recovery units, biological wastewater treatment systems, cryogenic unit and for the management of all tank farm operations.•Improved the performance, reliability and efficiency of Tech Service operations which were critical to successful manufacturing on site as part of EPA licence; achieved very significant improvements in MTTR, MTBF and cost reduction of >20%.

•Led the recruitment and training of 45 manufacturing technicians and shift managers. •Led the start- up of the manufacturing facility leading to successful validation campaigns and FDA and HPRA inspections.

Lead BMS End user team through all aspects of Design (Concept, FED, DD) and start up on new $500 million API facility

Managed the capacity increase of Paclitaxel production from sales of $30 million per year to over $1.5 billion in 4 years.